Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Akero Therapeutics, Inc. | 3,719,759 | reported | 24 Jun 2019 | tx 5+3,954,858−11,389,404 |
| Elevation Oncology, Inc. | 2,608,167 | reported | 29 Jun 2021 | tx 3+2,608,167−8,380,034 |
| VYNE Therapeutics Inc. | 22,500 | reported | 25 Jun 2019 | tx 2+45,000 |
| Ventyx Biosciences, Inc. | 21,825 | reported | 09 Jun 2022 | tx 6+4,032,395−3,684,769 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 09 Jun 2022 | GRANT_AWARD | Ventyx Biosciences, Inc. | 13,301 | 0.00 USD | deriv |
| 25 Oct 2021 | PURCHASE | Ventyx Biosciences, Inc. | 312,500 | 16.00 USD | |
| 25 Oct 2021 | CONVERSION | Ventyx Biosciences, Inc. | 3,684,769 | 0.00 USD | |
| 25 Oct 2021 | CONVERSION | Ventyx Biosciences, Inc. | 395,027 | 0.00 USD | deriv |
| 25 Oct 2021 | CONVERSION | Ventyx Biosciences, Inc. | 3,289,742 | 0.00 USD | deriv |
| 29 Jun 2021 | CONVERSION | Elevation Oncology, Inc. | 1,983,167 | — | |
| 29 Jun 2021 | PURCHASE | Elevation Oncology, Inc. | 625,000 | 16.00 USD | first after silence |
| 29 Jun 2021 | CONVERSION | Elevation Oncology, Inc. | 8,380,034 | 0.00 USD | deriv |
| 25 Jun 2019 | GRANT_AWARD | VYNE Therapeutics Inc. | 22,500 | 0.00 USD | deriv |
| 24 Jun 2019 | CONVERSION | Akero Therapeutics, Inc. | 235,099 | — | |
| 24 Jun 2019 | PURCHASE | Akero Therapeutics, Inc. | 250,000 | 16.00 USD | |
| 24 Jun 2019 | CONVERSION | Akero Therapeutics, Inc. | 3,469,759 | — | |
| 24 Jun 2019 | CONVERSION | Akero Therapeutics, Inc. | 722,737 | 0.00 USD | deriv |
| 24 Jun 2019 | CONVERSION | Akero Therapeutics, Inc. | 10,666,667 | 0.00 USD | deriv |
1 purchase reported after at least 12 months of silence — most recent on 29 Jun 2021.